中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03681 中国抗体-B

交易中 09-08 14:35:16

1.135

-0.010

-0.87%

最高1.150	最低1.120	成交量31.11万
今开1.125	昨收1.145	日振幅2.62%
总市值15.74亿	流通市值15.74亿	总股本13.87亿
成交额35.08万	换手率0.02%	流通股本13.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03681","market":"HK","secType":"STK","nameCN":"中国抗体-B","latestPrice":1.135,"timestamp":1788849262550,"preClose":1.145,"halted":0,"volume":311100,"delay":0,"changeRate":-0.00873362445414848,"floatShares":1387000000,"shares":1387000000,"eps":-0.09994674329441836,"marketStatus":"交易中","change":-0.01,"latestTime":"09-08 14:35:16","open":1.125,"high":1.15,"low":1.12,"amount":350839,"amplitude":0.026201,"askPrice":1.14,"askSize":30600,"bidPrice":1.125,"bidSize":6000,"shortable":0,"etf":0,"ttmEps":-0.15629559278047406,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788855000000},"marketStatusCode":2,"adr":0,"listingDate":1573488000000,"exchange":"SEHK","adjPreClose":1.145,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.537892,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03681","defaultTab":"news","newsList":[{"id":"1183883083","title":"中国抗体-B特别股东大会全票通过出售事项普通决议","url":"https://stock-news.laohu8.com/highlight/detail?id=1183883083","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183883083?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:11","pubTimestamp":1788772290,"startTime":"0","endTime":"0","summary":"2026年9月7日，中国抗体-B公告披露，公司当日在香港举行的股东特别大会已就出售事项相关普通决议案完成投票。投票结果显示，赞成票为315,774,215股，占投票股份100.000000%；反对票为0股，占0.000000%。公告显示，截至股东特别大会当日，公司已发行股份总数为1,386,638,336股，全部股份均享有出席并投票权利。本次会议的监票工作由香港中央证券登记有限公司负责。此前，公司已于2026年8月21日向股东发出会议通函及股东特别大会通告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188806436","title":"中国抗体-B发布2026年8月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1188806436","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188806436?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:58","pubTimestamp":1788339514,"startTime":"0","endTime":"0","summary":"中国抗体-B于2026年9月2日公布了截至2026年8月31日的股份变动月报表。公告显示，报告期内公司已发行的普通股总数为1,386,638,336股，与上月末保持一致，未有新增发行、购回或注销及库藏股份活动，股本结构保持稳定。本月内因此发行的新股数和从库藏股份转让的数量均为零，故报告期内未产生任何发行收入。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012650","title":"中国抗体-B(03681.HK)上半年研发成本持续加码 产品管线收获多项里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012650","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012650?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:35","pubTimestamp":1788186935,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111951756","title":"中国抗体-B2026年中期收入23.5百万元，经调整净亏损71.1百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111951756","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111951756?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:26","pubTimestamp":1788186396,"startTime":"0","endTime":"0","summary":"根据公告，报告期内，中国抗体-B实现收入23.5百万元，主要来自利息收入、政府补助与汇兑收益。同期经调整净亏损约为71.1百万元，较去年同期49.8百万元增加21.3百万元，同比增幅约42.77%。公告称，该幅度的主要原因包括在中国启动SM17用于治疗特应性皮炎的2期临床试验所产生的实验室与实验成本增加。管理费用由23.7百万元升至39.0百万元，主要受非现金股份支付的职工薪酬影响。经营活动所用现金流量净额为29.9百万元，上一年同期为26.9百万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"中国抗体-B2026年中期收入23.5百万元，经调整净亏损71.1百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161094697","title":"中国抗体-B拟2.80亿元出售苏州地块及厂房 将于2026年9月7日召开股东特别大会表决","url":"https://stock-news.laohu8.com/highlight/detail?id=1161094697","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161094697?lang=zh_cn&edition=full","pubTime":"2026-08-21 06:10","pubTimestamp":1787263833,"startTime":"0","endTime":"0","summary":"中国抗体-B8月21日公告称，公司已发出股东特别大会通告，计划于2026年9月7日10时在香港中环红棉路8号东昌大厦14楼3室召开股东特别大会，审议一项普通决议案。股东特别大会除审议批准、确认及追认上述买卖协议及相关交易外，还将授权董事会成员签署并处理实施出售事项所需的所有文件和事宜。为确认出席股东特别大会的资格，公司股份过户登记册将自2026年9月2日至2026年9月7日暂停办理过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171383213","title":"中国抗体-B（03681）拟于8月31日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1171383213","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171383213?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:05","pubTimestamp":1787137541,"startTime":"0","endTime":"0","summary":"中国抗体-B（03681）19日公告称，董事会已排期于2026年8月31日（星期一）召开会议，主要议程包括：\n1. 审议及批准本集团截至2026年6月30日止六个月的中期业绩及其发布；  \n2. 处理任何其他事项。\n公告同时披露，公司执行董事为梁瑞安博士；非执行董事为王小素女士、薛蕾女士及张健民博士；独立非执行董事为George William Hunter Cautherley先生、韩炳祖先生、李志明博士、李之秀女士及申楠先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199607179","title":"中国抗体-B（03681）将于9月7日召开股东特别大会并暂停股份过户登记","url":"https://stock-news.laohu8.com/highlight/detail?id=1199607179","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199607179?lang=zh_cn&edition=full","pubTime":"2026-08-18 21:05","pubTimestamp":1787058331,"startTime":"0","endTime":"0","summary":"中国抗体-B8月18日公告，公司计划于2026年9月7日（星期一）上午10时整在香港中环红棉路8号东昌大厦14楼3室召开股东特别大会，审议拟议出售苏州物业及设施事项，该交易被界定为主要交易。届时，公司将不受理任何股份转让登记。有关本次股东特别大会的具体事项，公司将在稍后寄发的通函及大会通告中进一步披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660646487","title":"中国抗体：执行董事兼首席运营官梁芳辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2660646487","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660646487?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:16","pubTimestamp":1787051760,"startTime":"0","endTime":"0","summary":"8月18日，中国抗体（03681）发布公告，梁芳已辞任公司执行董事及首席运营官，以便投放更多时间处理其他个人事务，之后将不在公司担任任何职位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844706975.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844706975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199162120","title":"中国抗体-B（03681）：执行董事兼首席营运官梁芳辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1199162120","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199162120?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:56","pubTimestamp":1787050614,"startTime":"0","endTime":"0","summary":"中国抗体-B（03681）8月18日公告，公司执行董事兼首席营运官梁芳已于2026年8月18日辞任，以便投入更多时间处理其他个人事务。辞任后，梁芳将不再于集团担任任何职务。\n公司董事会表示，梁芳与董事会并无意见分歧，也不知悉其辞任与任何需提请股东或香港联交所注意的事项有关。董事会对梁芳任内的贡献表示感谢，并祝愿其未来一切顺利。\n截至公告日期，公司董事会构成为：执行董事梁瑞安博士（兼董事会主席及首席执行官）；非执行董事王小素女士、薛蕾女士及张健民博士；独立非执行董事George William Hunter Cautherley先生、韩炳祖先生、李志明博士、李之秀女士及申楠先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113082309","title":"中国抗体-B（03681）公布董事会成员及三大委员会组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1113082309","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113082309?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:56","pubTimestamp":1787050566,"startTime":"0","endTime":"0","summary":"2026年8月18日，中国抗体制药有限公司发布公告，披露最新董事会成员名单及其在三大董事委员会中的任职情况。本次公告未披露任何更替或新增人事，仅列示各董事及其在董事会下设委员会中的具体职务。公司强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469010","title":"中国抗体-B(03681.HK)：梁芳辞任执行董事及首席营运官","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660469010?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:44","pubTimestamp":1787049883,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136429597","title":"中国抗体-B发布2026年7月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1136429597","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136429597?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:51","pubTimestamp":1786006262,"startTime":"0","endTime":"0","summary":"中国抗体制药有限公司于2026年8月6日披露了截至2026年7月31日的证券变动月报表。公告显示，本月公司注册股本未发生变动，仍保持在1,386,638,336股，且未进行任何新增发行、购回或注销活动，股本维持不变。截至本月底，该计划下仍可能发行或转让16,926,100股，若所有已授予期权悉数行使，预计合计可能发行或转让34,019,409股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782915","title":"港股异动 | 中国抗体-B(03681.HK)涨超12% 自免赛道持续高景气 公司构建差异化管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655782915?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:45","pubTimestamp":1785397537,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654021223","title":"自免赛道迎来爆发，中国抗体-B(03681)以差异化优势锚定成长机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2654021223","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654021223?lang=zh_cn&edition=full","pubTime":"2026-07-28 08:55","pubTimestamp":1785200100,"startTime":"0","endTime":"0","summary":"智通财经APP观察到，这样的行业变局，为中国抗体-B这种深耕自免赛道多年的创新药企提供了关键的机遇。自免赛道迎来价值爆发，SM17早期数据展现巨大潜力近年以来，全球创新药市场历经周期调整后逐步回暖，BD交易活跃度持续攀升。临床数据进一步印证产品差异化疗效。并且，在整个试验期间无严重不良事件，显示出了SM17的良好安全性。除了SM17之外，中国抗体在皮肤自免与骨质疏松等领域亦有差异化布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154154103","title":"中国抗体-B（03681.HK）主要交易通函寄发时间延后至2026年8月10日或之前","url":"https://stock-news.laohu8.com/highlight/detail?id=1154154103","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154154103?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:26","pubTimestamp":1785147967,"startTime":"0","endTime":"0","summary":"中国抗体-B于2026年7月27日公告，因需更多时间编制及落实相关资料，公司将延迟寄发有关建议出售苏州物业及设施的主要交易通函。原计划通函于2026年7月27日或之前寄发，最新时间表调整为2026年8月10日或之前寄发。公告由执行董事、主席兼首席执行官梁瑞安博士代表董事会发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117044628","title":"中国抗体-B（03681.HK）授出1,802.604万份购股权 行使价每股1.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117044628","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117044628?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:31","pubTimestamp":1784892704,"startTime":"0","endTime":"0","summary":"2026年7月24日，中国抗体-B公告称，董事会已根据2022年采纳并于2024年6月14日修订的购股权计划，于2026年7月24日向2名合资格人士合共授出18,026,040份购股权。每份购股权可认购1股公司股份，行使价为每股1.200港元，为以下两者中的较高者：①授予日期当日股份收市价1.200港元；②授予日前五个连续交易日股份平均收市价1.152港元。本次购股权的行使期为自归属开始日期起至2036年7月23日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120602623","title":"中国抗体-B更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120602623","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120602623?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:45","pubTimestamp":1783413912,"startTime":"0","endTime":"0","summary":"中国抗体-B于2026年7月7日发布截至2026年6月30日的股份变动月报表。报告显示，公司本月已发行普通股及库存股数均保持不变，已发行股本总额维持在1,386,638,336股，且不存在任何库存股。本月无因行使期权新增发行股份或库藏股转让，且未获得任何行使期权的资金收入。公告显示，公司月内无购回、注销或其他股份变动活动，符合香港联交所相关上市规则及法律法规要求。截至6月底，公司公共持股量达到了适用的最低要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649772629","title":"中国抗体-B：拟2.8亿元出售苏州工业园区物业及设施 预计亏损5634万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649772629","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649772629?lang=zh_cn&edition=full","pubTime":"2026-07-06 20:03","pubTimestamp":1783339380,"startTime":"0","endTime":"0","summary":"7月6日，中国抗体-B（03681）发布公告，公司全资附属公司杏联药业（苏州）与苏州宜工品源生物医药有限公司（买方）及苏州宜联生物医药有限公司（担保人）订立买卖协议，拟以2.8亿元出售位于苏州工业园区的工业用地及地上建筑物，总占地面积约4.32万平方米，总建筑面积约7.13万平方米。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607063795348786.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607063795348786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1229","BK1542","BK1258","BK1574","03913","03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120361888","title":"中国抗体-B宣布重大交易 以2.8亿元处置苏州物业及设施","url":"https://stock-news.laohu8.com/highlight/detail?id=1120361888","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120361888?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:26","pubTimestamp":1783337195,"startTime":"0","endTime":"0","summary":"中国抗体-B宣布，已达成一项重大资产处置协议，将位于苏州的物业及相关设施以人民币2.8亿元的价格出售。\n此举被视为公司优化资产结构、聚焦核心研发业务的重要战略步骤。通过本次交易，公司预期将获得可观的现金流入，用于支持其在新药研发领域的持续投入与拓展。\n市场分析人士指出，生物科技企业在发展过程中适时处置非核心资产，有助于提升运营效率并强化财务状况。此次交易的具体细节及后续资金用途，将持续受到投资者关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649262666","title":"中国抗体-B(03681.HK)附属拟2.8亿元出售苏州物业及设施","url":"https://stock-news.laohu8.com/highlight/detail?id=2649262666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649262666?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:24","pubTimestamp":1783337050,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1258","BK1161","03681","BK1574","03913","BK1542","BK1229"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinomab.com","stockEarnings":[{"period":"1week","weight":0.0409},{"period":"1month","weight":-0.1455},{"period":"3month","weight":0.0905},{"period":"6month","weight":-0.3974},{"period":"1year","weight":-0.5148},{"period":"ytd","weight":-0.1455}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司。该公司主要研制以单克隆抗体为基础的生物制剂和新化学实体, 主要产品包括治疗类风湿关节炎的潜在单抗药物SM03。 该公司研发药物还包括有治疗特应性皮炎，哮喘，特发性肺纤维化及其他免疫性疾病潜力的SM17以及针对系统性红斑狼疮, 天疱疮，多发性硬化症及视神经脊髓炎普系疾病的SN1011 。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.001496},{"month":2,"riseRate":0.428571,"avgChangeRate":0.047286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.044577},{"month":4,"riseRate":0.714286,"avgChangeRate":0.048474},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.024206},{"month":6,"riseRate":0.285714,"avgChangeRate":0.017188},{"month":7,"riseRate":0.428571,"avgChangeRate":0.073842},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.147299},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.035524},{"month":10,"riseRate":0,"avgChangeRate":-0.071195},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.003752},{"month":12,"riseRate":0.428571,"avgChangeRate":0.081979}],"exchange":"SEHK","name":"中国抗体-B","nameEN":"SINOMAB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国抗体-B,03681,中国抗体-B股票,中国抗体-B股票老虎,中国抗体-B股票老虎国际,中国抗体-B行情,中国抗体-B股票行情,中国抗体-B股价,中国抗体-B股市,中国抗体-B股票价格,中国抗体-B股票交易,中国抗体-B股票购买,中国抗体-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}